What's Happening?
Gilead Sciences announced robust financial results for the third quarter of 2026, with base business sales increasing by 16% year-over-year, marking its strongest growth in over a decade. This performance was primarily driven by strong sales of HIV treatments
like Biktarvy, Descovy, and Yeztugo, as well as oncology drug Trodelvy and liver disease treatment Livdelzi. The company reported total product sales of $8.3 billion, a 13% increase year-over-year. Following these strong results, Gilead has raised its full-year 2026 revenue guidance for the third time, now projecting total product sales between $31 billion and $31.3 billion. However, the company also disclosed that the Centers for Medicare & Medicaid Services (CMS) has set the price for Biktarvy at $2,600 per 30-day supply, representing a 38% discount from its list price in the Medicare channel. This federal pricing mandate is expected to result in a net impact of approximately $1.5 billion reduction in Biktarvy revenue in 2028.
Why It's Important?
Gilead's strong financial performance underscores the continued demand for its key pharmaceutical products, particularly in the HIV and oncology sectors. The increased revenue guidance signals confidence in its current portfolio and market position. However, the CMS-mandated price reduction for Biktarvy highlights the growing impact of federal drug pricing policies on pharmaceutical companies. This decision, stemming from the Maximum Fair Price determination process, could set a precedent for other high-value drugs, potentially affecting future revenue streams and investment in drug development across the industry. The projected $1.5 billion revenue hit for Biktarvy in 2028, while significant, is expected to be partially offset by growth in other areas of Gilead's diverse portfolio, including its HIV prevention and oncology segments. This situation illustrates the complex interplay between pharmaceutical innovation, market demand, and government efforts to control healthcare costs.
What's Next?
Gilead plans to continue advancing its diverse pipeline, which includes 49 clinical programs, to mitigate the anticipated revenue impact from Biktarvy's price reduction. The company expects to file for islatravir plus lenacapavir, a potential once-weekly oral HIV treatment, this year, with a regulatory decision anticipated in 2027. Additionally, Gilead is preparing for the potential launch of anito-cel for multiple myeloma, with a PDUFA date in December 2026. The company will also focus on expanding its inflammation and immunology portfolio, including the recent $1.4 billion acquisition of an oral IL-23 inhibitor program. Gilead aims to mitigate the $1.5 billion Biktarvy revenue impact through various strategies over the next year, while still projecting overall HIV revenue growth in 2028 compared to 2027, driven by other innovations in its portfolio. Further details on mitigation strategies and updated financial projections are expected as 2028 approaches.
Beyond the Headlines
The CMS decision on Biktarvy's pricing extends beyond immediate financial implications for Gilead, raising broader questions about the future of pharmaceutical innovation and drug accessibility in the U.S. The company's CEO, Daniel O'Day, stated that the price set by CMS 'does not reflect the value of Biktarvy' and could 'put investment in new medicines at risk,' particularly for small molecule drugs addressing diseases like HIV that disproportionately affect underserved populations. This 'pill penalty,' as described by O'Day, could discourage research and development in critical therapeutic areas. The situation highlights an ongoing tension between the pharmaceutical industry's need for profitability to fund innovation and public demands for more affordable medications. It also underscores the evolving landscape of drug pricing regulations, which could lead to long-term shifts in how pharmaceutical companies prioritize R&D investments and commercial strategies in the U.S. market.
